PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA

Erika Turkstra; Emilie Bettington; Maria L Donohue; Merehau C Mervin

doi:10.1017/S0266462317000617

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA

Erika Turkstra, Emilie Bettington, Maria L Donohue, Merehau C Mervin

Research output: Contribution to journal › Article

Abstract

Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Advisory Committee (PBAC) and assess whether the predicted financial impact was associated with a recommendation. The second objective was to assess whether the financial and utilization estimates for listing the proposed medicine were reliable

Original language	English
Pages (from-to)	521-528pp
Journal	International Journal of Technology Assessment in Health Care
Volume	33
Issue number	4
DOIs	https://doi.org/10.1017/S0266462317000617
Publication status	Published - 2017

Access to Document

10.1017/S0266462317000617

Cite this

@article{ca6b3c8cbcf84c6d9d6ab292e4921ddd,

title = "PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA",

abstract = "Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Advisory Committee (PBAC) and assess whether the predicted financial impact was associated with a recommendation. The second objective was to assess whether the financial and utilization estimates for listing the proposed medicine were reliable",

author = "Erika Turkstra and Emilie Bettington and Donohue, {Maria L} and Mervin, {Merehau C}",

year = "2017",

doi = "10.1017/S0266462317000617",

language = "English",

volume = "33",

pages = "521--528pp",

journal = "International Journal of Technology Assessment in Health Care",

issn = "0266-4623",

publisher = "Cambridge University Press",

number = "4",

}

TY - JOUR

T1 - PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA

AU - Turkstra, Erika

AU - Bettington, Emilie

AU - Donohue, Maria L

AU - Mervin, Merehau C

PY - 2017

Y1 - 2017

N2 - Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Advisory Committee (PBAC) and assess whether the predicted financial impact was associated with a recommendation. The second objective was to assess whether the financial and utilization estimates for listing the proposed medicine were reliable

AB - Objectives: The aim of this study was to examine submissions made to the Pharmaceutical Benefits Advisory Committee (PBAC) and assess whether the predicted financial impact was associated with a recommendation. The second objective was to assess whether the financial and utilization estimates for listing the proposed medicine were reliable

U2 - 10.1017/S0266462317000617

DO - 10.1017/S0266462317000617

M3 - Article

SN - 0266-4623

VL - 33

SP - 521

EP - 528

JO - International Journal of Technology Assessment in Health Care

JF - International Journal of Technology Assessment in Health Care

IS - 4

ER -

PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE RECOMMENDATIONS IN AUSTRALIA

Abstract

Access to Document

Fingerprint

Cite this